{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_mixture_components_substance_refPname in Mixture Component Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2001)
Source URL:
First approved in 2001
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA074612
(1999)
Source URL:
First approved in 1999
Source:
ANDA074612
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2022)
Source URL:
First approved in 1995
Source:
21 CFR 358H
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT01964547: Phase 4 Interventional Completed Multiple Sclerosis
(2012)
Source URL:
Class:
MIXTURE
Targets:
CB-13 is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood-brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. CB-13 displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.
Status:
Other
Class:
MIXTURE
Status:
US Previously Marketed
Source:
CENASERT IMPROVED METHYLBENZETHONIUM CHLORIDE by CENTRAL PHARCA
(1961)
Source URL:
First approved in 1947
Class:
MIXTURE
Status:
US Previously Marketed
Source:
CENASERT IMPROVED METHYLBENZETHONIUM CHLORIDE by CENTRAL PHARCA
(1961)
Source URL:
First approved in 1947
Class:
MIXTURE